Anti-VEGF therapy may revolutionize ROP treatment

A single intravitreal injection of an anti-VEGF agent in babies with retinopathy of prematurity

induces regression of pathological neovascularization and also promotes resumption of

physiological vascularization of the retina, Tim U Krohne MD of the University of Bonn Eye

Clinic told the World Society of Paediatric Ophthalmology & Strabismus. As such, it could

eliminate the need to ablate avascular retina tissue and has the potential to revolutionize ROP

treatment.

However, several issues must be addressed before anti-VEGF is adopted, Dr Krohne said. These

include establishing the smallest effective dose and assessing safety with particular attention to

systemic side effects. Injection sight is also an issue since premature infant eyes are very small.

The new IOL functional classification needs a strong and unified effort from surgeons, societies, and industry.

Professional and personal goals drive practice ownership and operational choices.

Improving access through financially and environmentally sustainable innovation.

New ideas and industry, colleague, and funding contacts among the benefits.

Partnerships with academia and industry promote innovation.

Endothelial damage, cellular treatments, human tissue, and infections are key concerns on the horizon.

Surgeons may prefer some IOLs for their patients, but what about for themselves?

This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.

Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.